title: Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease.
abstract: BACKGROUND
  Adamantiades-Behçet's disease (ABD) is a multi-system disorder with recurrent oral and/or genital ulcerations, skin lesions and ocular involvement. Eye involvement is a common manifestation that affects the patients' quality of life more than any other. Left untreated, it leads to blindness and often to loss of the eye through secondary complications like phthisis or painful glaucoma. In some cases, such as tractional retinal detachment, secondary glaucoma or secondary cataract formation, intraocular surgery is required.
  
  
  METHODS
  A prospective study of patients with ocular ABD who underwent intraocular surgery under systemic treatment with interferon-alpha was conducted. From 1999 to 2005, we treated eight eyes from five patients with pars plana vitrectomy (n = 1), phacoemulsification (n = 6) and trabeculectomy (n = 1). The mean follow-up was 49 months (range 5-94 months).
  
  
  RESULTS
  Seven out of eight eyes had better visual acuity following surgery. One eye did not benefit from cataract surgery because of optic nerve atrophy. Only one eye showed prolonged inflammation following phacoemulsification. None of the patients showed a recurrence during follow-up. The failure of conservative glaucoma treatment necessitated trabeculectomy in one eye; the patient has had no further recurrence for 6 years under monotherapy with interferon-alpha.
  
  
  CONCLUSIONS
  Interferon-alpha is a potent therapy for Adamantiades-Behçet's disease with ocular involvement. It also provides a basis for safe and reliable surgical interventions. In seven of eight eyes, there was no intra- or peri-operative recurrence of inflammation, which is a common complication after these procedures. Only one eye showed acute and prolonged inflammation following cataract surgery.
authors: Department of Ophthalmology, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. lothar.krause@charite.de
authors: Lothar
authors: L
authors: Krause
authors: Andreas
authors: A
authors: Altenburg
authors: Nikolaos E
authors: NE
authors: Bechrakis
authors: Gregor
authors: G
authors: Willerding
authors: Christos C
authors: CC
authors: Zouboulis
authors: Michael H
authors: MH
authors: Foerster
mesh_terms: D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D018918:Phacoemulsification; D011446:Prospective Studies; D011994:Recombinant Proteins; D012827:Silicone Oils / Q000008:administration & dosage; D013459:Sulfur Hexafluoride / Q000008:administration & dosage; D014130:Trabeculectomy; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012827:Silicone Oils; D013459:Sulfur Hexafluoride